Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC reduced its stake in shares of Arvinas, Inc. (NASDAQ:ARVN) by 4.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,422 shares of the company’s stock after selling 1,460 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Arvinas were worth $757,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. American International Group Inc. increased its stake in Arvinas by 1.8% in the first quarter. American International Group Inc. now owns 24,857 shares of the company’s stock valued at $1,026,000 after purchasing an additional 449 shares during the period. Principal Financial Group Inc. increased its stake in Arvinas by 3.8% in the first quarter. Principal Financial Group Inc. now owns 13,307 shares of the company’s stock valued at $549,000 after purchasing an additional 486 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Arvinas by 9.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 12,570 shares of the company’s stock valued at $519,000 after purchasing an additional 1,060 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Arvinas in the first quarter valued at $44,000. Finally, ProShare Advisors LLC increased its stake in Arvinas by 18.8% in the first quarter. ProShare Advisors LLC now owns 13,832 shares of the company’s stock valued at $571,000 after purchasing an additional 2,188 shares during the period. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on ARVN shares. Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a research note on Monday. HC Wainwright restated a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a research note on Thursday, August 1st. Wedbush reiterated an “outperform” rating and set a $57.00 price target on shares of Arvinas in a research note on Tuesday, July 30th. Oppenheimer dropped their price target on shares of Arvinas from $70.00 to $50.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 31st. Finally, Barclays dropped their price target on shares of Arvinas from $60.00 to $48.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. Two analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Arvinas Trading Down 1.5 %

ARVN stock opened at $24.51 on Friday. The company has a market cap of $1.68 billion, a P/E ratio of -4.13 and a beta of 1.97. Arvinas, Inc. has a 52 week low of $13.57 and a 52 week high of $53.08. The company’s 50-day moving average price is $26.49 and its 200 day moving average price is $32.00.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($1.08) by $0.59. The company had revenue of $76.50 million for the quarter, compared to analysts’ expectations of $33.27 million. During the same period in the prior year, the firm posted ($1.25) EPS. The firm’s quarterly revenue was up 40.4% on a year-over-year basis. On average, equities research analysts expect that Arvinas, Inc. will post -3.51 earnings per share for the current year.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.